[go: up one dir, main page]

GB1035701A - Emulsions suitable for use as adjuvants for immunological agents - Google Patents

Emulsions suitable for use as adjuvants for immunological agents

Info

Publication number
GB1035701A
GB1035701A GB8958/64A GB895864A GB1035701A GB 1035701 A GB1035701 A GB 1035701A GB 8958/64 A GB8958/64 A GB 8958/64A GB 895864 A GB895864 A GB 895864A GB 1035701 A GB1035701 A GB 1035701A
Authority
GB
United Kingdom
Prior art keywords
aqueous phase
oil
oleate
oils
mixing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB8958/64A
Inventor
Allen Francis Woodhour
Thomas Bernard Stim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to GB8958/64A priority Critical patent/GB1035701A/en
Publication of GB1035701A publication Critical patent/GB1035701A/en
Priority to CY39767A priority patent/CY397A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Vaccine adjuvants, for use as vehicles for administration of injectable immunalogical substances, comprise a water-in-oil emulsion consisting on a volume basis of 20 to 75% of vegetable oil; 1.25 to 25% of mannide mono-oleate; 0.5 to 5% of aluminium monostearate, and sufficient aqueous phase to bring the volume to 100%. The emulsion is prepared by mixing the oil and mannide mono-oleate portion wise, adding the aluminium salt, and heating with simultaneous mixing, until the aluminium salt is dispersed and thixotropy sets in; the solution is then cooled to room temperature, and the aqueous phase added in portions, with suitable mechanical emulsification. Preferred oils are peanut, sesame, chaulmoogra, corn, alive, cottonseed, sweet almond, or persic oils. A further emulsifying agent (e.g. Polysorbate 80) may be included. The vaccine, preferably a purified or partially purified antigen, is added to the aqueous phase before addition of the latter to the oil phase. The aqueous phase may be for example, water, suitable saline solution, phosphate buffered saline, or tissue culture fluid, and may contain preservatives or other conventional vaccine additives. Antigens specified are those derived from bacteria, viruses, rickettsia, pollen, dust, danders, poisons or venoms of insects or reptiles, or multiple (mixed) antigens.ALSO:The invention comprises a water-in-oil emulsion, comprising, on a volume basis: 20 to 75% vegetable oil; 1.25 to 25% of mannide mono-oleate; 0.5 to 5% of aluminium monostearate, and sufficient aqueous phase to bring the volume to 100%. The composition is prepared by mixing the vegetable oil and the mannide mono-oleate, combining the mixture with the aluminium monostearate, followed by slow heating of the resulting product with mixing to a temperature where the aluminium salt is dispersed, and thixotropy sets in. The solution is then cooled to room temperature and the aqueous phase added in portions with emulsification by suitable mechanical means. Optionally a secondary emulsifying agent (e.g. polysorbate 80) may be included. Preferred vegetable oils are peanut, sesame, corn, olive, cottonseed, sweet almond, persic, and chaulmoogra oils. The emulsion is for use as an adjurant for injectable inmunological substances (see Division A5).
GB8958/64A 1964-03-03 1964-03-03 Emulsions suitable for use as adjuvants for immunological agents Expired GB1035701A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB8958/64A GB1035701A (en) 1964-03-03 1964-03-03 Emulsions suitable for use as adjuvants for immunological agents
CY39767A CY397A (en) 1964-03-03 1967-06-08 Emulsions suitable for use as adjuvants for immunological agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8958/64A GB1035701A (en) 1964-03-03 1964-03-03 Emulsions suitable for use as adjuvants for immunological agents

Publications (1)

Publication Number Publication Date
GB1035701A true GB1035701A (en) 1966-07-13

Family

ID=9862596

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8958/64A Expired GB1035701A (en) 1964-03-03 1964-03-03 Emulsions suitable for use as adjuvants for immunological agents

Country Status (2)

Country Link
CY (1) CY397A (en)
GB (1) GB1035701A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187286A1 (en) * 1984-12-20 1986-07-16 BEHRINGWERKE Aktiengesellschaft Oil-adjuvated vaccine and its manufacturing process
USRE32393E (en) * 1967-09-01 1987-04-07 Kabivitrum Ab Composition for enhancing the administration of pharmacologically active agents
CN114796477A (en) * 2022-04-25 2022-07-29 广西农业职业技术大学 Preparation method of hemp seed oil adjuvant inactivated vaccine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32393E (en) * 1967-09-01 1987-04-07 Kabivitrum Ab Composition for enhancing the administration of pharmacologically active agents
EP0187286A1 (en) * 1984-12-20 1986-07-16 BEHRINGWERKE Aktiengesellschaft Oil-adjuvated vaccine and its manufacturing process
CN114796477A (en) * 2022-04-25 2022-07-29 广西农业职业技术大学 Preparation method of hemp seed oil adjuvant inactivated vaccine

Also Published As

Publication number Publication date
CY397A (en) 1967-06-08

Similar Documents

Publication Publication Date Title
Aucouturier et al. Adjuvants designed for veterinary and human vaccines
CA2008856C (en) Tocols as adjuvant in vaccine
DE3787663T2 (en) Vaccine formulation.
JP2648305B2 (en) Polysaccharide vaccine
US3149036A (en) Adjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agent
AU655155B2 (en) Vaccines and vectors with liquid active principles containing an oil which can be metabolised
ES2061054T3 (en) INJECTABLE MULTIPHASE EMULSIONS.
SU1375113A3 (en) Method of producing emulsion of 9- 2-oxyethoxymethyl guanine "aciclovir" and method of producing emulsion of 9- (2-oxyethoxymethyl) guanine
ATE9870T1 (en) FAT EMULSION CONTAINING A STEROID.
RU2006135121A (en) MICROFLUIDIZED EMULSIONS OF THE TYPE "OIL IN WATER" AND VACCINE COMPOSITIONS
JPH09506353A (en) Adjuvant for antigen, its production method and use
RU2009113834A (en) MICROFLUIDIZED EMULSIONS “OIL IN WATER” AND VACCINE COMPOSITIONS
GB1171125A (en) Improvements in or relating to Injectable Preparations
GB1372008A (en) Water-in-oil emulsions
JPH0639386B2 (en) Production method of live adjuvant vaccine
DE69730393T2 (en) Vaccine compositions containing inactivated immunogens and live chicken anemia viruses
DE2603321A1 (en) EMULSION BASED ON A METABOLIZABLE VEGETABLE OIL AND WATER
DE69910253T2 (en) METHOD FOR PRODUCING INACTIVATED, W / O EMULSION ADJUVED, VACCINALS
GB1035701A (en) Emulsions suitable for use as adjuvants for immunological agents
US3240670A (en) Injectable pharmaceutical emulsions containing liquid organopolysiloxanes
Davis et al. The transmission of neurotropic yellow fever virus by stegomyia mosquitoes
US6221403B1 (en) Topical composition
Schoenberg et al. The cellular response of the spleen and its relationship to the circulating 19S and 7S antibody in the antigenically stimulated rabbit
WO2000037045B1 (en) Stabilized water-in-oil-in-water antigen delivery system
US3435112A (en) Repository vaccine and method of preparing the same